GlycoMimetics Inc (NASDAQ:GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases, announced on Tuesday that it has entered into an acquisition agreement with privately held biotechnology company Crescent Biopharma Inc.
The combined company will focus on advancing Crescent's pipeline of oncology therapeutics, including the tetravalent PD-1 x VEGF bispecific antibody CR-001 which is expected to have preliminary proof of concept data in the second half of 2026. Additionally, Crescent is developing two novel antibody-drug conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003.
A syndicate of investors has committed USD200m to fund operations through 2027.
Pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company, with the pre-acquisition Crescent stockholders owning approximately 96.9%.
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Sichuan Kelun-Biotech reveals sacituzumab tirumotecan (sac-TMT) clinical studies results
Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial
EDX Medical launches new testicular cancer detection test in UK
Oncolytics Biotech signs share purchase agreement with Alumni Capital
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
MaaT Pharma receives positive DSMB safety recommendation for Phase 2b trial of MaaT033